Lantheus Holdings

LNTH

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding

In their latest 13F (Q3 2026)

See who

Value held

$888k

Combined value at quarter end

Last quarter

1 bought

0 sold or trimmed

Price at Q2 ’26 end

$110.94

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Managers holding it, by quarter

0Q4 ’23

0Q1 ’24

0Q2 ’24

0Q3 ’24

0Q4 ’24

0Q1 ’25

0Q2 ’25

0Q3 ’25

0Q4 ’25

0Q1 ’26

1Q2 ’26

0Q3 ’26

Counts the managers on this site whose 13F for that quarter includes Lantheus Holdings.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Lantheus Holdings

First Eagle Investment Management	0.0%$888k	$888k	New	1 qtr

Download the holders: CSV · JSON · Markdown

About the company

Sector: Health care · In Vitro & In Vivo Diagnostic Substances
Incorporated in: Delaware
Financial year ends: 31 December
Shares outstanding: 65m at 3 Aug 2026
SEC filings: Annual reports and other filings on EDGAR

Revenue and profit

$284m2013

$293m2015

$331m2017

$347m2019

$425m2021

$1.3bn2023

$1.5bn2025

Lantheus Holdings revenue and net income by year
Year	Revenue	Net income
2025	$1.5bn	$234m
2024	$1.5bn	$312m
2023	$1.3bn	$327m
2022	$935m	$28.1m
2021	$425m	−$71.3m
2020	$339m	−$13.5m
2019	$347m	$31.7m
2018	$343m	$40.5m
2017	$331m	$123m
2016	$302m	–
2015	$293m	–
2014	$302m	–
2013	$284m	–

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.